Investor Presentation – 22 April 2021 at 1400 BST

Destiny Pharma plc
(“Destiny Pharma” or the “Company”)

Investor Presentation

Brighton, United Kingdom – 15 April 2021 – Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce that Neil Clark and Shaun Claydon will provide a live presentation relating to Full Year Results for year ending 31 December 2020 via the Investor Meet Company platform on 22 April 2021 at 2 pm BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9 am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Destiny Pharma via:

https://www.investormeetcompany.com/destiny-pharma-plc/register-investor

Investors who already follow Destiny Pharma on the Investor Meet Company platform will automatically be invited.

Enquiries:

Destiny Pharma plc
+44 (0) 12 7370 4440
Neil Clark (Chief Executive Officer)
Shaun Claydon (Chief Financial Officer and Company Secretary)

finnCap Limited – Nominated Adviser and Joint Broker
+44 (0) 20 7220 0500
Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)
Alice Lane (ECM)

WG Partners LLP – Joint Broker
+44 (0) 20 3705 9330
Nigel Barnes / Claes Spång / Nigel Birks / Andrew Craig

Optimum Strategic Communications
+44 (0) 20 3174 1789
Mary Clark / Shabnam Bashir / Manel Mateus

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infections in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information on the Company, please visit www.destinypharma.com